

Thermo Fisher introduces new assay to help advance future of precision medicine

15 July 2025 | News

Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System



US-based Thermo Fisher Scientific has announced that the Oncomine™ Comprehensive Assay Plus is now available on the Ion Torrent™ Genexus™ System helping accelerate precision oncology research.

The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows.

CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximise insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily.

The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day.